Pathway-centric structure-based multi-target compound screening for anti-virulence drug repurposing
The emergence of superbugs that are resistant to last-resort antibiotics poses a serious
threat to human health, and we are in a “race against time to develop new antibiotics.” New …
threat to human health, and we are in a “race against time to develop new antibiotics.” New …
hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation
RW Mercier, Y Pei, L Pandarinathan, DR Janero… - Chemistry & biology, 2010 - cell.com
The human cannabinoid 2 GPCR (hCB2) is a prime therapeutic target. To define potential
cysteine-related binding motifs critical to hCB2-ligand interaction, a library of hCB2 cysteine …
cysteine-related binding motifs critical to hCB2-ligand interaction, a library of hCB2 cysteine …
Recent advances in the development of pyrazole derivatives as anticancer agents
Y Zhang, C Wu, N Zhang, R Fan, Y Ye, J Xu - International Journal of …, 2023 - mdpi.com
Pyrazole derivatives, as a class of heterocyclic compounds, possess unique chemical
structures that confer them with a broad spectrum of pharmacological activities. They have …
structures that confer them with a broad spectrum of pharmacological activities. They have …
Pyridine: the scaffolds with significant clinical diversity
The nitrogen-bearing heterocycle pyridine in its several analogous forms occupies an
important position as a precious source of clinically useful agents in the field of medicinal …
important position as a precious source of clinically useful agents in the field of medicinal …
Synthesis and vectorial functionalisation of pyrazolo [3, 4-c] pyridines
EV Bedwell, F da Silva Emery, GC Clososki, PG Steel - RSC advances, 2023 - pubs.rsc.org
Heterocycles are a cornerstone of fragment-based drug discovery (FBDD) due to their
prevalence in biologically active compounds. However, novel heterocyclic fragments are …
prevalence in biologically active compounds. However, novel heterocyclic fragments are …
A comprehensive review on recent developments in the field of biological applications of potent pyrazolines derived from chalcone precursors
Background: Pyrazoline scaffold is a key structural motif found among pharmaceutically
active molecules including synthetic and natural products. The molecules with pyrazoline …
active molecules including synthetic and natural products. The molecules with pyrazoline …
Enhancing drug efficacy and therapeutic index through cheminformatics-based selection of small molecule binary weapons that improve transporter-mediated …
The transport of drug molecules is mainly determined by the distribution of influx and efflux
transporters for which they are substrates. To enable tissue targeting, we sought to develop …
transporters for which they are substrates. To enable tissue targeting, we sought to develop …
Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class
E Salah, E Ugochukwu, AJ Barr… - Journal of medicinal …, 2011 - ACS Publications
ABL2 (also known as ARG (ABL related gene)) is closely related to the well-studied Abelson
kinase cABL. ABL2 is involved in human neoplastic diseases and is deregulated in solid …
kinase cABL. ABL2 is involved in human neoplastic diseases and is deregulated in solid …
Exploring the untapped pharmacological potential of imidazopyridazines
MS Malik, HF Alshareef, KA Alfaidi, H Ather… - RSC …, 2024 - pubs.rsc.org
Imidazopyridazines are fused heterocycles, like purines, with a pyridazine ring replacing the
pyrimidine ring in purines. Imidazopyridazines have been primarily studied for their kinase …
pyrimidine ring in purines. Imidazopyridazines have been primarily studied for their kinase …
Direct and sequential bioactivation of pemigatinib to reactive iminium ion intermediates culminates in mechanism-based inactivation of cytochrome P450 3A
We recently established the mechanism-based inactivation (MBI) of cytochrome P450 3A
(CYP3A) by the fibroblast growth factor receptor (FGFR) inhibitors erdafitinib and infigratinib …
(CYP3A) by the fibroblast growth factor receptor (FGFR) inhibitors erdafitinib and infigratinib …